Page 171 - CW E-Magazine (30-4-2024)

News from Abroad News from Abroad

ANIONIC SURFACTANTS stance. This new facility, which is partly and Watertown, Massachusetts, in the
Vantage expanding taurate capabilities at German funded by a Job Development Invest- US, Fujifi lm Diosynth said in a recent
ment Grant from the state of North
business update.
facility Carolina, allows for further expansions The CDMO revealed that it is
with additional bioreactors, clearing the
way for future partnerships. The facility reworking its small-scale business unit
US-based maker of bio-based ingre- taps into Fujifl m’s KojoX modular pro- after taking hits from “the short-term
dients built on core surfactant chemis- duction model, which supports supply impacts of reduced venture capital
tries, Vantage Specialty Chemicals, is chain resiliency by allowing customers suite at the new plant, which should be investment into early-stage research
expanding taurate capacity at its manu- to integrate their drug manufacturing fully operational in 2025. projects”. The lack of investment is
facturing site in Leuna, Germany. The production needs regardless of facility particularly notable in the cell and gene
company said the expansion is aimed location. Small-scale business revamp therapy fi elds, according to the company.
at meeting customer demand and In another development, Fujifi lm The restructuring of the small-scale
anticipated market growth in end mar- In March 2021, Fujifi lm Diosynth Diosynth Biotechnologies announced group is aimed at improving its opera-
kets such as personal care, laundry and Biotechnologies had fi rst announced the decision to globally restructure its tional and fi nancial performance.
household, industrial and institutional Taurine) capacity to target demand in relates to approximately 1,000-tpa of that Holly Springs had been selected small-scale medicines business unit
(HI&I). the personal care market. The “multi- CO emissions. for the location of the company’s $2-bn (which deals with products in their Other than those listed for potential
2
million-dollar” investment is a two- biomanufacturing facility. In November early research and clinical stages), that cuts, Fujifi lm also has a small-scale unit
Taurates are anionic surfactants phase expansion that will almost triple “The additional capacity will allow 2023, the company announced that may result in up to 240 jobs being cut. facility in Thousand Oaks, California.
with excellent foaming in the presence the site’s capacity for this building us to meet global demand for mild sur- Janssen Supply Group, LLC, a Johnson & This impacts employees at its Teesside Large-scale operations take place at
of sebum. They thicken with amphote- block. The initial phase was completed factants, particularly in personal care Johnson subsidiary, had committed to sites in the UK, and sites in College Denmark and the upcoming Holly
rics and salt, particularly at low pH and in September 2022 with the second where formulators favour our effective, occupy a large-scale manufacturing Station, Texas, Raleigh, North Carolina Springs site.
are stable over broad pH ranges. These phase expected to come online in early sulphate-free surfactant portfolio for
ingredients are ideal for facial washes, 2025. applications targeting sensitive skin CordenPharma and Genepep complete a year
low pH anti-acne treatments, high pH and scalp irritation,” said Mr. Steve
fatty acid soap formulations, intimate In addition to adding capacity, the Doktycz, CEO of the company. of offering peptides expertise
hygiene, hair dyes as well as low pH investment in the latest technology
shampoos. and state-of-the-art equipment will Vantage’s Leuna site is its largest Swiss CDMO CordenPharma and aging CordenPharma’s cGMP manufac- including testing reports, process fami-
further strengthen energy effi ciency at in the Europe, Middle East & Africa Genepep, a French CRO specialising turing capacities, regulatory know-how liarisation, and development.
Vantage is specifi cally expanding the site, reducing steam consumption (EMEA) region and became part of in the design, chemical synthesis, and and market access, as well as Genepep’s
its Metaupon branded NMT (N-Methyl by approximately 40% annually which Vantage in 2019. optimisation of peptides, peptide libraries discovery and drug development exper- In addition, they supply gram pep-
and proteins, are celebrating one year of tise. Under the terms of the agreement, tide manufacturing samples represent-
EXPANSION their collaboration. Genepep provides services for R&D ative of tox quality, ensuring a smooth
Fujifi lm investing $1.2-bn to boost cell culture The partnership, signed in 2023, sup- activities, as well as support for initial and seamless transition to the Corden-
Pharma Frankfurt site for early clinical
Investigational New Drug (IND) appli-
manufacturing capabilities in US ports biotech companies with the deve- cation packages, including selection of GMP manufacturing, along with access
to their global sales and marketing
lopment, discovery, and manufacturing lead and alternative compounds for dis-
of peptides for early clinical phase, lever- covery purpose, research-grade samples organisation.
Fujifi lm Diosynth Biotechnologies, support additional large-scale
the contract manufacturing subsidiary production capacity to the Philadelphia to host CPHI North America 2024
of Japan’s Fujifi lm Corporation, has company’s global manufac-
announced an additional $1.2-bn in- turing network, creating an in May
vestment in its large-scale cell culture additional 680 jobs by 2031.
contract development and manufac- CPHI North America, the pharma 350 exhibitors and the addition of three industry can exhibit their new products
turing organisation (CDMO) business The investment in the industry trade fair organised by Informa new zones – covering sustainability, and solutions. This year’s conference
through an expansion to its end-to-end Holly Springs facility will Markets, is scheduled to be held innovation, and growth & develop- will feature four tracks – ‘Sustainable
bio-manufacturing facility in Holly add eight 20,000 litres (L) from 7-9 May, 2024 at Pennsylvania ment (designed to help promote job Futures’, ‘Revolutionising Drug Manu-
Springs, North Carolina (USA). This mammalian cell culture bio- Convention Centre in Philadelphia, opportunities and encourage career facturing’, ‘Supply Chain Economy’,
expansion brings the total investment reactors by 2028, adding to USA. development conversations) – along- and ‘Exploring Excipients’ – as well as
in the Fujifi lm Diosynth Biotechno- the initially planned eight side a ‘Start-Up Market’ where smaller a breakfast session on manufacturing
logies facility to over $3.2-bn and will 20,000-L for bulk drug sub- The 2024 event will feature over innovators and enterprises from the excellence and a CDMO roundtable.

170 Chemical Weekly April 30, 2024 Chemical Weekly April 30, 2024 171

Contents Index to Advertisers Index to Products Advertised